UY27177A1 - Novedosos derivados heterocíclicos de la urea y sus usos como ligandos del receptor d3 de la dopamina. - Google Patents

Novedosos derivados heterocíclicos de la urea y sus usos como ligandos del receptor d3 de la dopamina.

Info

Publication number
UY27177A1
UY27177A1 UY27177A UY27177A UY27177A1 UY 27177 A1 UY27177 A1 UY 27177A1 UY 27177 A UY27177 A UY 27177A UY 27177 A UY27177 A UY 27177A UY 27177 A1 UY27177 A1 UY 27177A1
Authority
UY
Uruguay
Prior art keywords
dopamine
urea
links
receiver
heterocyclic derivatives
Prior art date
Application number
UY27177A
Other languages
English (en)
Inventor
James A Hendrix
Horst Hemmerle
Matthias Urmann
Joseph T Strupczewski
Kenneth J Bordeau
Sarah Brooks
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of UY27177A1 publication Critical patent/UY27177A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a novedosos derivados heterocíclicos sustituidos de la urea que muestran selectivo enlace a los receptores D3 de la dopamina. En otro aspecto, la invención se refiere a un método de tratamiento de desórdenes del sistema nervioso central asociados con la actividad del receptor D3 de la dopamina en un paciente con necesidad de tales tratamientos que comprende la administración al sujeto de una cantidad terapéuticamente efectiva de dichos compuestos para aliviar tales desórdenes.
UY27177A 2001-02-16 2002-02-18 Novedosos derivados heterocíclicos de la urea y sus usos como ligandos del receptor d3 de la dopamina. UY27177A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26965401P 2001-02-16 2001-02-16

Publications (1)

Publication Number Publication Date
UY27177A1 true UY27177A1 (es) 2002-09-30

Family

ID=23028129

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27177A UY27177A1 (es) 2001-02-16 2002-02-18 Novedosos derivados heterocíclicos de la urea y sus usos como ligandos del receptor d3 de la dopamina.

Country Status (7)

Country Link
US (1) US20030229066A1 (es)
JP (1) JP2009196997A (es)
CO (1) CO5390077A1 (es)
GB (1) GB0117950D0 (es)
PA (1) PA8540201A1 (es)
PT (1) PT1392676E (es)
UY (1) UY27177A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117577D0 (en) * 2001-02-16 2001-09-12 Aventis Pharm Prod Inc Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D receptor ligands
MXPA05007513A (es) * 2003-01-14 2005-09-21 Cytokinetics Inc Compuestos, composiciones y metodos.
BRPI0512193B8 (pt) * 2004-06-17 2021-05-25 Cytokinetics Inc composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
KR101033290B1 (ko) * 2004-07-02 2011-05-09 주식회사 엘지생명과학 다이아이소프로필((1-(하이드록시메틸)-사이클로프로필)옥시)메틸포스포네이트의 새로운 제조 방법
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
EP1959947A2 (en) * 2005-12-15 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
EP1962852B1 (en) * 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
AU2008280187B2 (en) 2007-07-26 2013-05-16 F. Hoffmann-La Roche Ag Dual modulators of 5-HT2A and D3 receptors
US20110098322A1 (en) * 2007-08-06 2011-04-28 The Regents Of The University Of California Preparation of novel 1,3-substituted ureas as inhibitors of soluble epoxide hydrolase
US8877778B2 (en) 2010-12-15 2014-11-04 Hoffmann-La Roche Inc. Benzofurane compounds
US8921397B2 (en) 2011-05-04 2014-12-30 Hoffmann-La Roche Inc. Benzofurane-piperidine compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK181190D0 (da) * 1990-07-30 1990-07-30 Lundbeck & Co As H 3-aryl-indol- eller 3-aryl-indazolderivater
US5245028A (en) * 1990-08-09 1993-09-14 Warner-Lambert Company Process for preparing tetracyclic amines useful as cerebrovascular agents
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
PL346247A1 (en) * 1998-08-18 2002-01-28 Ucb Sa Muscarinic agonists and antagonists

Also Published As

Publication number Publication date
JP2009196997A (ja) 2009-09-03
US20030229066A1 (en) 2003-12-11
CO5390077A1 (es) 2004-04-30
PA8540201A1 (es) 2003-06-30
GB0117950D0 (en) 2001-09-19
PT1392676E (pt) 2007-02-28

Similar Documents

Publication Publication Date Title
UY27177A1 (es) Novedosos derivados heterocíclicos de la urea y sus usos como ligandos del receptor d3 de la dopamina.
UY27343A1 (es) Ligandos del receptor de 5-ht y sus usos
CR6436A (es) Inhibidores de la receptacion de monoaminas para el tratamiento de trastornos del snc
WO2004058717A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
EP1363632A4 (en) SELECTIVE CANNABIMIMETIC AMINOALKYLINDOLES OF A RECEPTOR
ECSP088402A (es) Compuestos y composiciones que contienen diarilamina, y su utilización como moduladores de los receptores c-kit
ECSP055613A (es) Derivados de pirimidina y su uso como moduladores cb2
AR029199A1 (es) Derivados de adenosina n6 heterociclico 5&#39;-tio- sustituidos agonistas a1 parciales o totales, sus usos, y sus composiciones farmaceuticas
DOP2009000155A (es) Derivados de hetero-pentaciclo-fenilo fusionados, composicion farmaceutica que los comprende y usos para preparar un medicamento util para el tratamiento de una condicion mediada por p38
PA8493701A1 (es) Compuestos para tratar la obesidad
UY28750A1 (es) Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina
HN2003000207A (es) Moduladores del receptor de glucocorticoides
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
CU23293B7 (es) Derivados de 2-oxo-1-pirrolidina para prepararlos y sus usos
BRPI0519031A2 (pt) compostos e composiÇÕes como moduladores de atividades de receptores esteroidais e de canal de cÁlcio
CL2011002206A1 (es) Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras.
NI200700032A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
NO985599D0 (no) Arylsubstituerte, sykliske aminer som selektive dopamin D3-ligander
NO20021035D0 (no) Fremgangsmåter for anvendelse av rasktvirkende selektive serotonin gjenopptakningsinhibitorer for behandling av seksuelldysfunksjon
DOP2009000255A (es) Extrudidos con enmascaramiento del sabor mejorado
PA8494601A1 (es) Nuevas combinaciones farmaceuticas para inhibidores de la nos
PE20011049A1 (es) Combinacion de farmacos para el tratamiento de la depresion y trastornos relacionados que comprenden mirtazapina
PA8801501A1 (es) ARILINDENOPIRIMIDINAS Y SU USO COMO ANTAGONISTAS DEL RECEPTOR A 2a DE ADENOSINA
PA8567701A1 (es) Agonistas del receptor b3-adrenergico

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20111129